Navigation Links
LA BioMed investigator Dr. Christina Wang spearheads study on new male contraceptive gel
Date:6/28/2012

Christina Wang, M.D., lead investigator at Los Angeles Biomedical Research Institute (LA BioMed) one of the leading biomedical research institutes in the country recently completed a study utilizing a new contraceptive gel that has the potential to be developed as a user controlled chemical birth control agent for males. The gel, which contains testosterone and a synthetic progestin called Nestorone, sharply lowers sperm counts in men with few side effects. The study conducted at LA BioMed and the University of Washington is funded by the National Institutes of Child Health and Human Development (NICHD).

Dr. Wang and her team, along with the team at the University of Washington, enrolled 99 men in a preliminary study of the drug combination. One third of them received a gel containing testosterone and a placebo, which was applied for six months. The remaining two thirds received a gel containing testosterone and one of the two concentrations of Nestorone. Fifty-six men completed at least 20 weeks of the study and adhered to the protocol.

The results of the study were reported at the recent Endocrine Society Meeting & Expo in Houston. Of the men receiving the drug combination, 88 to 89 percent achieved a sperm concentration of less than 1 million sperm per milliliter, while those receiving testosterone and the placebo achieved the same low sperm concentration in 23 percent of men. Depending on the dosage, there was a complete absence of sperm in 78 and 69 percent of the men receiving the drug combination, and in 23 percent of the men receiving testosterone and the placebo.

"Up until now, the responsibility for contraception has traditionally always been with the female," said Dr. Wang. "With these new contraceptive methods for males, the responsibility will be shared. While this gel has great potential and minimal side effects, it does warrant further study as a male contraceptive."

Dr. Wang is a renowned andrologist/endocrinologist and a world leader in efforts to develop a safe, effective and reversible hormonal male contraceptive. In addition to this study, she is also working on a Phase I single dose and multiple dose study that tests the safety and tolerability of a new androgen dimethandrolone undecanoate that is being developed as a potential male contraceptive agent by the National Institute of Child Health and Human Development.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
2. UMMS researcher Victor Ambros, Ph.D., named co-recipient of 2012 Janssen Award for Biomedical Research
3. UCSC physicist Alexander Sher named Pew Scholar in the Biomedical Sciences
4. Applied nanobiomedicine: Exploiting nanoparticles to hunt for hidden cancer cells
5. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
6. LA BioMed receives Grand Challenges Explorations grant
7. Biomedical researchers receive Hartwell Foundation awards
8. LA BioMeds Dr. John Tsuang examines effects of Ibudilast and metamphetamines
9. Leading health care quality expert is 2012 AcademyHealth Distinguished Investigator
10. Damon Runyon Cancer Research Foundation awards $3.3 million to 8 top young clinical investigators
11. Pediatric kidney expert receives Young Investigator Award from American Transplant Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 09, 2016 , ... Dr. Rassouli, cosmetic dentist in Orange County , ... most popular cosmetic procedures in dentistry today, but the cost often leads to patients ... risk of teeth whitening-related damage. For a limited time, Dr. Rassouli is offering this ...
(Date:2/9/2016)... ... 2016 , ... United Methodist Communications collaborated with Chocolate Moose ... video designed to prevent the next widespread Ebola outbreak from occurring ... distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and other African countries, ...
(Date:2/8/2016)... ... ... CURE Media Group , the nation’s leading digital and print media enterprise ... , which will annually honor individuals making heroic contributions in the field of multiple ... Awards nomination process is officially open through February 17 for patients, caregivers and ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Valentine’s Season is famous for gift giving with flowers, ... that they are loved. This year, for more than 5.6 million Americans suffering with ... won't be enough to remind them of the lives they’ve led and the people they’ve ...
(Date:2/8/2016)... ... February 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving ... program, has teamed up with Citizens Opposed to Domestic Abuse in support of its ... support all those victimized by the fear of violence in their own homes, donations ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... LONDON , Feb. 9, 2016 The new report ... Spearhead Acuity Business Research & Consulting group reveals that the ... market with a share of 38.9% in 2014 that translated into ... , Europe , Asia-Pacific ... and Africa . The global anti-bacterial market ...
(Date:2/8/2016)... Feb.8, 2016 Respiratory Devices - Medical ... Medical Devices sector report, " Respiratory Devices - ... overview of Respiratory Devices currently in pipeline stage. ... pipeline products with comparative analysis of the products ... major players involved in the pipeline product development. ...
(Date:2/8/2016)... FAIRFIELD, N.J. , Feb. 8, 2016  Otsuka ... today announced that they have entered into a licensing ... OPA-15406 in the U.S. and Puerto Rico ... is a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a ... --> --> In a Phase II ...
Breaking Medicine Technology: